Phase 3 N=1,809 Comparative Study of Three NNRTI-Sparing HAART Regimens
HIV Infection
Primary: Cumulative Probability of First Virologic Failure by Week 96 — 13; 10; 15 cumulative probability per 100 persons
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=102 A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
Pneumococcal Disease
Primary: Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine — 0.2; 0.2; 4.1; 2.5 ug/mL
Phase 3 N=60 Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery
Cataract
Primary: Deviation From Intended Capsulotomy Diameter — 26.8; 339.1 μm
Phase 3 N=123 Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B
Severe Hemophilia B
Primary: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities — 2; 0; 2; 0 participants
Phase 3 N=404 Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Bipolar Disorder, Pediatric
Primary: Change From Baseline in Y-MRS Total Score at Day 21 — -9.6; -12.3; -15.1; -15.9 score on a scale — p=0.008
Phase 3 N=1,132 Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12 — 0.313; 0.196 Area Under the Curve (L) — p=<0.0001
Phase 3 N=150 Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
Congenital Bleeding Disorder · Haemophilia A
Primary: The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)) — 0 N with Inhibitors / N with ≥50 EDs
Phase 3 N=160 A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Gaucher Disease, Type 1
Primary: Percentage of Participants Who Remained Stable for 52 Weeks During the Primary Analysis Period — 84.8; 93.6 percentage of participants
Phase 3 N=40 A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
Gaucher Disease, Type 1
Primary: PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared…
Phase 3 N=667 TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Early Clinical Response Rate — 264; 266 Responders
Phase 3 N=1,095 Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
Low Back Pain
Primary: The "Average Pain Over the Last 24 Hours" at Week 12 of the Double-blind Period — 3.86; 4.32 units on a scale (0 - 10) — p=0.0055
Phase 3 N=30 Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
Rheumatoid Arthritis · Insulin Resistance
Primary: Insulin Sensitivity Index — 7.7; 7.7; 8.1; 7.8 (dL x L)/(mg x mIU) — p=0.930
Phase 3 N=238 Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
Asthma
Primary: Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period…
Phase 3 N=248 Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
Asthma
Primary: Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period…
Phase 3 N=220 Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
Prostate Cancer
Primary: Median and Between Participant Variability of Time to Prostate-specific Antigen (PSA) >4 ng/mL During the First Cycle of Intermittent Androgen Deprivation (IAD) After 7…